News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RxBio, Inc., Biopharmaceutical Affiliate of University of Tennessee Health Science Center, Receives $15 Million Federal Contract from Biomedical Advanced Research and Development Authority


11/8/2011 7:58:13 AM

MEMPHIS, Tenn.--(BUSINESS WIRE)--The University of Tennessee Health Science Center (UTHSC) is pleased to announce that RxBio, Inc., an early stage biopharmaceutical company that has spun out of the University of Tennessee Health Science Center (UTHSC), has been awarded a $15 million federal contract. The contract will fund the further development of Rx100, the company’s potent radiomitigant countermeasure drug, which may protect against the potentially lethal effects from radiation exposure. To date, no such drug has been approved by the Food and Drug Administration. The U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) contract is valued at up to $24 million ($15 million in the base contract; $9 million in options) over the next two years.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES